AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8896529
Drug: DTPa vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa vaccine
Trial: 3720707
Drug: Extended phenytoin
RxNorm normalized name: Extended Phenytoin Sodium Capsules
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended phenytoin sodium capsules (Dilantin Kapseals) - 3 capsules of 100 mg each (276 mg free acid)
Trial: 3720707
Drug: Phenytoin oral
RxNorm normalized name: phenytoin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin oral suspension (Dilantin oral suspension) - 11 ml (275 mg)
Trial: 27340358
Drug: Oral E.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E. coli Nissle therapy (2 capsules daily for one month)
Trial: 27340358
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vegetarian diet and topical therapy only)
Trial: 9002328
Drug: Treatment algorithm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment algorithm (including locally available foods, vitamin and mineral supplementation, selective use of antibiotics)
Trial: 9449728
Drug: Limited-ventilation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited-ventilation group (peak inspiratory pressure maintained at 30 cm of water or less, tidal volume at 8 ml per kilogram or less)
Trial: 2627387
Drug: IV labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV labetalol at doses of 0.25, 0.5, 0.75, or 1 mg/kg
Trial: 31901229
Drug: Peri-articular injection
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-articular injection (PAI)
Trial: 31901229
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection (IAI)
Trial: 31254462
Drug: Prolonged capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged capecitabine chemotherapy (1000 mg/m² per day for 2 weeks, repeated every 3 weeks for 8 cycles at most)
Trial: 31254462
Drug: Prolonged capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged capecitabine chemotherapy
Trial: 31254462
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prolonged chemotherapy)
Trial: 28323965
Drug: Daily recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily recombinant human GH (r-hGH) at a dose of 0.24 mg/kg/wk
Trial: 21044831
Drug: SOD/gliadin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOD/gliadin supplement (500 mg/day for 12 weeks)
Trial: 13342
Drug: Group discussion‐placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group discussion‐placebo control treatment (n = 4)
Trial: 23471421
Drug: Centralized depression
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centralized depression care (patient preference for problem-solving treatment via telephone or Internet, pharmacotherapy, both, or neither) for 6 months (active treatment group; n = 73)
Trial: 11507918
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene program (instruction on brushing, flossing, and professional tooth cleaning)
Trial: 11507918
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control (10 students with no oral hygiene training)
Trial: 9022536
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg D‐alpha‐tocopheryl acetate plus 250 mg slow‐release ascorbic acid twice a day (n = 20)
Trial: 9022536
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg D‐alpha‐tocopheryl acetate twice a day (n = 20)
Trial: 9022536
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ascorbic acid twice a day (n = 21)
Trial: 9022536
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg slow‐release ascorbic acid twice a day (n = 21)
Trial: 9022536
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day (n = 20)
Trial: 28957341
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy course
Trial: 16096787
Drug: Angiotensin 1-7
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin 1-7 (A(1-7)) administered at a dose of 100 microg/kg per day for at least 10 days after chemotherapy.
Trial: 16096787
Drug: Filgrastim (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (control group) administered over three cycles of chemotherapy.
Trial: 12885265
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream 0.1% applied to face (standard application)
Trial: 12885265
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream 0.1% applied to 15% body surface area (exaggerated application)
Trial: 12885265
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream 0.1% applied to face (standard application) in photodamaged skin
Trial: 12885265
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream 0.1% applied to 15% body surface area (exaggerated application) in photodamaged skin
Trial: 11115436
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone (125 mg)
Trial: 4024909
Drug: TTS‐scopolamine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTS‐scopolamine (two patches)
Trial: 4024909
Drug: Dimenhydrinate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate (100 mg)
Trial: 20016142
Drug: Overall Ca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall Ca absorption
Trial: 17296655
Drug: Three-times-daily (TID)
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-times-daily (TID) heparin dosing
Trial: 12186604
Drug: Hydrocortisone (50-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50-micro g tablet once daily)
Trial: 10452638
Drug: Rifabutin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin (300 mg/d)
Trial: 8267679
Drug: Bromfenac 25
RxNorm normalized name: bromfenac 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 25 mg
Trial: 2357869
Drug: Bromfenac 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 10 mg and 25 mg
Trial: 9690243
Drug: Bromfenac 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 5 mg
Trial: 9675655
Drug: Symptomatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic drugs (control group)
Trial: 30630815
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg and 75 mg on two following days)
Trial: 30630815
Drug: Gemfibrozil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (600 mg BID for 5 days)
Trial: 19767074
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (30mg/d for 14 days)
Trial: 3538945
Drug: Ketanserin (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (after initial treatment with placebo)
Trial: 3538945
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after initial treatment with ketanserin)
Trial: 3538945
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in crossover treatment)
Trial: 3538945
Drug: Ketanserin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (in crossover treatment)
Trial: 24337154
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion (48 h, 30 ml/h)
Trial: 15860854
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) IV every 3 weeks (AC)
Trial: 10190766
Drug: Ferrous-glycine-sulfate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous-glycine-sulfate (200 mg elemental iron daily)
Trial: 2085987
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol (FT, 3 g)
Trial: 2085988
Drug: Cotrimoxazole (CTX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (CTX, 960 mg, 3 times daily)
Trial: 479908
Drug: Combined histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined histamine H1 and H2 antagonist treatment
Trial: 9491827
Drug: Loratadine-pseudoephedrine (L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine-pseudoephedrine (L + PS)
Trial: 6099707
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous cyclophosphamide
Trial: 17091024
Drug: Sequential estradiol‐norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential estradiol‐norethisterone acetate regimen for 3 months
Trial: 16770976
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) injections plus standard clinical care
Trial: 11480653
Drug: Titratable oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titratable oral appliance in mandibular position MAX67
Trial: 11480653
Drug: Titratable oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titratable oral appliance in mandibular position MAX
Trial: 11480653
Drug: Titratable oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titratable oral appliance in mandibular position RP
Trial: 9428829
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate (400 mg/day for 14 days followed by 76 days of elemental calcium 500 mg/day)
Trial: 18698246
Drug: Methyl aminolevulinate
RxNorm normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl aminolevulinate (MAL) photodynamic therapy
Trial: 18698246
Drug: Control (lesion-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (lesion-specific treatment, 83% cryotherapy)
Trial: 12075764
Drug: Oral, killed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, killed enterotoxigenic Escherichia coli plus cholera toxin B-subunit vaccine
Trial: 9524014
Drug: cilazapril 2
RxNorm normalized name: cilazapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril 2 x 2.5 mg
Trial: 200357
Drug: Involved-field irradiation
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved-field irradiation and further chemotherapy
Trial: 15383183
Drug: Quetiapine (300.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (300.5 mg/day mean dose, maximum 686.0 mg/day)
Trial: 9012298
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) infusion at 1.5 micrograms/kg/min
Trial: 17949799
Drug: i.v. pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. pegylated liposomal doxorubicin (PLD) (30 mg/m2) plus i.v. carboplatin (AUC=5 mg/mL min) once every 4 weeks
Trial: 17949799
Drug: i.v. carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. carboplatin alone (AUC=5 mg/mL min) once every 4 weeks
Trial: 8794442
Drug: E2-DG (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2-DG (1.5 mg E2 for 24 days with 0.15 mg DG for the last 12 days followed by 1 placebo tablet for 4 days)
Trial: 3080291
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including antacid use)
Trial: 23018440
Drug: Drug conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug conservation group
Trial: 23018440
Drug: Drug conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug conservation participants on fully suppressive ART
Trial: 16679825
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Lycopene (6 mg/day), Beta-carotene (4.8 mg/day), Alpha-tocopherol (10 mg/day), Selenium (75 microg/day)
Trial: 18297254
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 mg)
Trial: 11200748
Drug: BAL fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL fluid from s.B in sarcoidosis patients (2.64 pg/ml)
Trial: 8825532
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg piroxicam given two hours preoperatively
Trial: 8825532
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg piroxicam given immediately before induction of anaesthesia
Trial: 1451729
Drug: Quinidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (50 mg orally)
Trial: 6371535
Drug: Dipyridamole (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (225 mg per day) and Aspirin (975 mg per day)
Trial: 30254135
Drug: Rifaximin 400
RxNorm normalized name: Rifaximin 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 400 mg three times a day for 2 weeks, then 200 mg three times a day for a further 2 weeks
Trial: 21232664
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel for 6 months
Trial: 21232664
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol at discharge
Trial: 21232664
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel at discharge
Trial: 21232664
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAT) - aspirin, clopidogrel, and cilostazol at 6 months
Trial: 21232664
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAT) - aspirin and clopidogrel at 6 months
Trial: 19235536
Drug: Symptomatic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapies
Trial: 17028293
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (300 U/kg), administered three times weekly starting 10 to 14 days before and continuing throughout radiotherapy.
Trial: 17028293
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered under double-blind conditions.
Trial: 31630117
Drug: Programmed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed treatment group (3 mg/kg IFX until week 6, then dose adjusted based on baseline TNF-α levels until week 54)
Trial: 27469171
Drug: Taper-integrated screwed-in
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper-integrated screwed-in (TIS) implants
Trial: 27469171
Drug: Both TIF
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TIF and TIS implants
Trial: 8996712
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) plus buspirone
Trial: 8996712
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) plus placebo
Trial: 8241011
Drug: Metoprolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (15 mg as a bolus intravenously, followed by an infusion of 0.04 mg/kg/hr)
Trial: 3310369
Drug: Phenylpropanolamine (PPA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (PPA), 50 mg twice daily
Trial: 23525499
Drug: rIPC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIPC with disulfiram (600 mg od)
Trial: 12712486
Drug: aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprepitant 125 mg on Day 1 and 80 mg on Days 2-5
Trial: 12712486
Drug: aprepitant 40
RxNorm normalized name: aprepitant 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprepitant 40 mg on Day 1 and 25 mg on Days 2-5
Trial: 12712486
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy (intravenous ondansetron plus oral dexamethasone)
Trial: 1349294
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose infusion
Trial: 8158512
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Oral hygiene instructions with scaling and root planing
Trial: 8158512
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Oral hygiene instructions without subgingival scaling and root planing
Trial: 16793562
Drug: Niacin extended-release/lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin extended-release/lovastatin (500/20 mg) once daily
Trial: 16793562
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg) once daily
Trial: 2179366
Drug: Long-term continuous
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term continuous subcutaneous infusion of large doses of salbutamol (greater than 14 mg/day)
Trial: 6986067
Drug: Cefadroxil 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 2,000 mg once daily
Trial: 4016827
Drug: Cefadroxil 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 1,000 mg once daily
Trial: 6986067
Drug: Cefadroxil 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 1,000 mg twice daily
Trial: 30597803
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg L-1 flumequine (FLU)
Trial: 26255764
Drug: 6 weekly
RxNorm normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weekly fractions (fx/w) of radiotherapy
Trial: 26255764
Drug: 5 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 weekly fractions (fx/w) of radiotherapy
Trial: 23369174
Drug: Sites group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sites group (treatment)
Trial: 18087797
Drug: Buprenorphine 16
RxNorm normalized name: buprenorphine 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 16 mg + naloxone 4 mg/day
Trial: 11552215
Drug: Aprotinin infusion
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin infusion (1,000,000-KIU loading dose, followed by 250,000-KIU/h infusion during surgery)
Trial: 7709944
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g elemental calcium)
Trial: 2691233
Drug: Tetracycline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (500 mg four times daily for a week)
Trial: 22292366
Drug: Dengzhan group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengzhan group (fleabane injection and Dengzhan Shengmai capsules)
Trial: 16464386
Drug: Urinastatin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinastatin treatment (300 kU for severe burns, 200 kU for moderate burns) administered intravenously twice a day for 5 to 7 days
Trial: 16464386
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received routine therapy
Trial: 15471303
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without protective HI antibody to A (H3N2)
Trial: 9349062
Drug: Cisatracurium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.1 mg.kg‐1 followed by infusion of 3 micrograms.kg‐1.min‐1
Trial: 9349062
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg.kg‐1 followed by infusion of 10 micrograms.kg‐1.min‐1